Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Tobacco smoke - Cigarette smoking

And/or tobacco substitutes. PMID 22365253, 23001806, 23999882. Passive smoking (secondhand smoke) may cause part of these manifestations, particularly in children. Review on imaging of smoking-related ILD: PMID 24480144. Tobacco smoking may alter the pharmacokinetics of anticancer agents, being detrimental in terms of therapeutic efficacy (PMID: 24926542). Smoking in survivors of Hodgkin's and other malignant lymphomas should be discouraged, as risk of developing lung cancer is makedly increased. Reviews at PMID 25415179, 25415179, 25498399, 29222007. Imaging and pathology at PMID 26479130.

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d

Acute eosinophilic pneumonia (AEP)
I.g

Pulmonary fibrosis
I.i

Subclinical pulmonary infiltrates/ILD
I.k

Exogenous lipoid pneumonia (subacute, acute)
I.s

An imaging pattern consistent with DIP
I.aj

Combined pulmonary fibrosis and emphysema syndrome (CPFE)

XLIII - Airway involvement

XLIII.a

Bronchospasm - Wheezing - Asthma
XLIII.l

Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)
XLIII.v

Endobronchial (eosinophilic) nodules on bronchoscopy
XLIII.ab

Cough (lone)
XLIII.ae

Cough syncope
XLIII.ag

Obstructive airway dysfunction (see also IVc, XVx)

XLIV - Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.as

Tracheal injury
XLIV.ax

Tracheitis including eosinophilic tracheal inflammation

XLVIII - Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.q

Obstructive sleep apnea

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.o

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
XLIX.z

ANCA positivity. Subclinical or with clinical manifestations
XLIX.ae

Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
XLIX.aj

Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

L - Miscellaneous

L.k

Pulmonary emphysema - Lung cysts or bullae
L.ad

Vertebral compression fracture
L.ae

Fainting
L.ak

Disrupted lung surfactant function

LIII - Hemoglobinopathies - Abnormal hemoglobin states (acquired)

LIII.b

Carboxyhemoglobinemia

LV - Imaging

LV.g

Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)
LV.p

Imaging: Small irregular opacities - ILA - Diffuse reticulation - 'Dirty lung'
LV.ae

Imaging: A generalized increase in lung density

LVIII - Pathology

LVIII.k

Path: Desquamative interstitial pneumonia (DIP-pattern)
LVIII.y

Path: Smoking-related interstitial fibrosis (SRIF). Respiratory bronchiolitis with fibrosis
LVIII.ap

Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern)
LVIII.aq

Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
LVIII.cn

Path: Airspace enlargement with fibrosis

LIX - Infections & related conditions

LIX.a

Respiratory tract infection incl. pneumonia

LX - Neoplastic conditions

LX.a

Lung cancer